Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature

L. Pinkas, P. D. Robins, L. A. Forstrom, D. W. Mahoney, B. P. Mullan

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

A retrospective study was carried out to determine the diagnostic value of OncoScint CR/OV immunoscintigraphy in assessing patients with suspected recurrence of carcinoma of the colon and ovary. The scintigraphic results of 31 patients were compared with surgical and histopathological findings, conventional radiological examinations and clinical disease outcome over an average 3-year follow-up. Detected lesions were divided by location into hepatic or extrahepatic and the latter group was classified as local recurrence at the resection site, pelvic or abdominal regional lymph node involvement and distant metastatic disease. The combined sensitivity and accuracy of immunoscintigraphy in the detection of extrahepatic disease was significantly higher than that of cross-sectional radiological imaging (87% and 83% vs 44% and 53% respectively) with equal specificity of 74%. Scintigraphy identified 14(36%) of 39 extrahepatic malignant lesions not diagnosed by conventional radiological techniques and influenced therapeutic planning in 8 (26%) of 31 patients studied. In the liver, conventional imaging had a significantly higher detection rate than immunoscintigraphy (sensitivity 93% vs 28%). In conclusion, these results show that OncoScint scintigraphy is a sensitive method for the detection of local recurrence and extrahepatic metastases in colorectal and ovarian carcinoma and has an important role in the therapeutic decision-making process.

Original languageEnglish (US)
Pages (from-to)689-696
Number of pages8
JournalNuclear Medicine Communications
Volume20
Issue number8
StatePublished - 1999

Fingerprint

Colorectal Neoplasms
Monoclonal Antibodies
Recurrence
Radionuclide Imaging
Liver
Ovary
Decision Making
Colon
Retrospective Studies
Lymph Nodes
Neoplasm Metastasis
Carcinoma
Therapeutics
Indium 111In-satumomab pendetide

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature. / Pinkas, L.; Robins, P. D.; Forstrom, L. A.; Mahoney, D. W.; Mullan, B. P.

In: Nuclear Medicine Communications, Vol. 20, No. 8, 1999, p. 689-696.

Research output: Contribution to journalArticle

Pinkas, L. ; Robins, P. D. ; Forstrom, L. A. ; Mahoney, D. W. ; Mullan, B. P. / Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature. In: Nuclear Medicine Communications. 1999 ; Vol. 20, No. 8. pp. 689-696.
@article{b0a56b58d558477e833704dfd1d3392a,
title = "Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature",
abstract = "A retrospective study was carried out to determine the diagnostic value of OncoScint CR/OV immunoscintigraphy in assessing patients with suspected recurrence of carcinoma of the colon and ovary. The scintigraphic results of 31 patients were compared with surgical and histopathological findings, conventional radiological examinations and clinical disease outcome over an average 3-year follow-up. Detected lesions were divided by location into hepatic or extrahepatic and the latter group was classified as local recurrence at the resection site, pelvic or abdominal regional lymph node involvement and distant metastatic disease. The combined sensitivity and accuracy of immunoscintigraphy in the detection of extrahepatic disease was significantly higher than that of cross-sectional radiological imaging (87{\%} and 83{\%} vs 44{\%} and 53{\%} respectively) with equal specificity of 74{\%}. Scintigraphy identified 14(36{\%}) of 39 extrahepatic malignant lesions not diagnosed by conventional radiological techniques and influenced therapeutic planning in 8 (26{\%}) of 31 patients studied. In the liver, conventional imaging had a significantly higher detection rate than immunoscintigraphy (sensitivity 93{\%} vs 28{\%}). In conclusion, these results show that OncoScint scintigraphy is a sensitive method for the detection of local recurrence and extrahepatic metastases in colorectal and ovarian carcinoma and has an important role in the therapeutic decision-making process.",
author = "L. Pinkas and Robins, {P. D.} and Forstrom, {L. A.} and Mahoney, {D. W.} and Mullan, {B. P.}",
year = "1999",
language = "English (US)",
volume = "20",
pages = "689--696",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature

AU - Pinkas, L.

AU - Robins, P. D.

AU - Forstrom, L. A.

AU - Mahoney, D. W.

AU - Mullan, B. P.

PY - 1999

Y1 - 1999

N2 - A retrospective study was carried out to determine the diagnostic value of OncoScint CR/OV immunoscintigraphy in assessing patients with suspected recurrence of carcinoma of the colon and ovary. The scintigraphic results of 31 patients were compared with surgical and histopathological findings, conventional radiological examinations and clinical disease outcome over an average 3-year follow-up. Detected lesions were divided by location into hepatic or extrahepatic and the latter group was classified as local recurrence at the resection site, pelvic or abdominal regional lymph node involvement and distant metastatic disease. The combined sensitivity and accuracy of immunoscintigraphy in the detection of extrahepatic disease was significantly higher than that of cross-sectional radiological imaging (87% and 83% vs 44% and 53% respectively) with equal specificity of 74%. Scintigraphy identified 14(36%) of 39 extrahepatic malignant lesions not diagnosed by conventional radiological techniques and influenced therapeutic planning in 8 (26%) of 31 patients studied. In the liver, conventional imaging had a significantly higher detection rate than immunoscintigraphy (sensitivity 93% vs 28%). In conclusion, these results show that OncoScint scintigraphy is a sensitive method for the detection of local recurrence and extrahepatic metastases in colorectal and ovarian carcinoma and has an important role in the therapeutic decision-making process.

AB - A retrospective study was carried out to determine the diagnostic value of OncoScint CR/OV immunoscintigraphy in assessing patients with suspected recurrence of carcinoma of the colon and ovary. The scintigraphic results of 31 patients were compared with surgical and histopathological findings, conventional radiological examinations and clinical disease outcome over an average 3-year follow-up. Detected lesions were divided by location into hepatic or extrahepatic and the latter group was classified as local recurrence at the resection site, pelvic or abdominal regional lymph node involvement and distant metastatic disease. The combined sensitivity and accuracy of immunoscintigraphy in the detection of extrahepatic disease was significantly higher than that of cross-sectional radiological imaging (87% and 83% vs 44% and 53% respectively) with equal specificity of 74%. Scintigraphy identified 14(36%) of 39 extrahepatic malignant lesions not diagnosed by conventional radiological techniques and influenced therapeutic planning in 8 (26%) of 31 patients studied. In the liver, conventional imaging had a significantly higher detection rate than immunoscintigraphy (sensitivity 93% vs 28%). In conclusion, these results show that OncoScint scintigraphy is a sensitive method for the detection of local recurrence and extrahepatic metastases in colorectal and ovarian carcinoma and has an important role in the therapeutic decision-making process.

UR - http://www.scopus.com/inward/record.url?scp=0032706773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032706773&partnerID=8YFLogxK

M3 - Article

C2 - 10451876

AN - SCOPUS:0032706773

VL - 20

SP - 689

EP - 696

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 8

ER -